Neil Woodford’s troubled fund: what I’d do with Hargreaves Lansdown shares now

Hargreaves Lansdown’s share price fell 22% over last month due to its support for Neil Woodford’s fund, but is it worth buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Online fund supermarket and broker Hargreaves Lansdown (LSE: HL) has been a market sweetheart, with a price increase of more than 10 times since its IPO in 2007. The company’s activity, which consists in directing investors’ money to the “best-buy” funds, has mainly benefited from the pension reform and the growth of SIPPs to gain a 40% share of the UK self-directed investment market.

The development of online brokers has made investment in asset-managed funds and ETFs more widespread. The freedom to invest in alternative pension funds was a major innovation at the time, and allowed Hargreaves Lansdown to attract 1.1m people to invest through its platform.

Loss of investor confidence

Until recently, Neil Woodford’s Patient Capital Trust was one of Hargreaves Lansdown’s favourite funds.

Hargreaves’ customers accounted for about 20% of all the money invested in Patient Capital. Despite the disappointing performance of Mr Woodford’s fund, Hargreaves supported him until the end. This is a loss of credibility from my point of view, and trust is central to this business.

Investor confidence (and a lot of money) has been lost in this case. Hargreaves’ customers, who hold £2.1 billion invested in WPCT, have lost about a third of their investment in the last month alone. I do not think that Hargreaves Lansdown’s reputation can recover from backing Woodford’s judgement through these troubled times  and I fear that investor confidence in the company might be lost forever.

My view

These two shares will now follow two different paths, in my opinion. I am much more optimistic about WPTC because the shares trade at a discount of the fund’s assets value, and if Mr Woodford leaves then the investors might return.

On the other hand, Hargreaves Lansdown is not cheap. The shares started trading at about £2 in 2007 and, at the current price of £18.80, this represents a performance of around 850% over the 12-year period or about 25% per year.

Despite the Equity Income Fund scandal and WPTC’s poor performance, Hargreaves Lansdown is still up by about 3% a year to date. With a current price-to-earnings ratio of 38.17, Hargreaves appears expensive and its dividend yield of 1.62% isn’t all that attractive, either.

What next?

The next earnings season in August promises to be interesting because Hargreaves has the highest revenue target in its history, with an expected turnover of £245m.

I don’t see how this objective could be achieved because the extent of the damage is not yet known, and this uncertainty might penalise the share price until then. The decision to cut fees, announced by the company’s CEO, for clients who have invested in WPTC reinforces this view. And, in the long term, the loss of investor confidence might well further depress the share price.

CORRECTION: The original version of this article incorrectly stated that “WPCT… regularly ranked at the top of  the Wealth 50 list”.  However, it has never been on this list.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Jean-Philippe does not own shares in any company mentioned. The Motley Fool UK has recommended Hargreaves Lansdown. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »